Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Buy
54
RVPH Quote, Financials, Valuation and Earnings
Last price:
$1.78
Seasonality move
:
-10.48%
Day range:
$1.54 - $1.84
52-week range:
$0.60 - $5.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
4.3M
Avg. volume:
3.7M
1-year change:
-61.64%
Market cap:
$59.5M
Revenue:
--
EPS (TTM):
-$1.09
Analysts' Opinion
-
Consensus RatingReviva Pharmaceuticals Holdings has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.80, Reviva Pharmaceuticals Holdings has an estimated upside of 731.46% from its current price of $1.78.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing -574.16% downside risk from its current price of $1.78.
Fair Value
-
According to the consensus of 4 analysts, Reviva Pharmaceuticals Holdings has 731.46% upside to fair value with a price target of $14.80 per share.
RVPH vs. S&P 500
-
Over the past 5 trading days, Reviva Pharmaceuticals Holdings has overperformed the S&P 500 by 23.5% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Reviva Pharmaceuticals Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Reviva Pharmaceuticals Holdings has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Reviva Pharmaceuticals Holdings reported revenues of --.
Earnings Growth
-
Reviva Pharmaceuticals Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Reviva Pharmaceuticals Holdings reported earnings per share of -$0.25.
Enterprise value:
54M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.62x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$20.5M | -$41.6M | -$34.1M | -$11.6M | -$8.5M | |
| EBITDA | -$19.9M | -$41.9M | -$33.3M | -$11.3M | -$8.4M | |
| Diluted EPS | -$1.09 | -$1.89 | -$1.09 | -$0.48 | -$0.25 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $33.9M | $24M | $5.4M | $6.8M | |
| Total Assets | -- | $33.9M | $24M | $5.4M | $7.6M | |
| Current Liabilities | -- | $973.7K | $3.6M | $13M | $17.5M | |
| Total Liabilities | -- | $1.6M | $3.7M | $13.9M | $17.6M | |
| Total Equity | -- | $32.3M | $20.4M | -$8.5M | -$10M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18.2M | -$24.1M | -$33.3M | -$6.2M | -$4.2M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | $7.9M | $5.9M | $33.9M | -- | $3.6M | |
| Free Cash Flow | -$18.2M | -$24.1M | -$33.3M | -$6.2M | -$4.2M | |
RVPH
Sector
Market Cap
$59.5M
$46.1M
Price % of 52-Week High
31.39%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-61.64%
-30.52%
Beta (5-Year)
-0.023
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$1.75
200-day SMA
Buy
Level
$1.69
Bollinger Bands (100)
Buy
Level
0.86 - 1.64
Chaikin Money Flow
Buy
Level
24.7M
20-day SMA
Buy
Level
$1.72
Relative Strength Index (RSI14)
Buy
Level
53.03
ADX Line
Buy
Level
9.47
Williams %R
Buy
Level
-81.4332
50-day SMA
Buy
Level
$1.39
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
210.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer’s disease, and Parkinson’s disease psychosis and its other drug candidate is RP1208.
Stock Forecast FAQ
In the current month, RVPH has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The RVPH average analyst price target in the past 3 months is $14.80.
-
Where Will Reviva Pharmaceuticals Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Reviva Pharmaceuticals Holdings share price will rise to $14.80 per share over the next 12 months.
-
What Do Analysts Say About Reviva Pharmaceuticals Holdings?
Analysts are divided on their view about Reviva Pharmaceuticals Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Reviva Pharmaceuticals Holdings is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Reviva Pharmaceuticals Holdings's Price Target?
The price target for Reviva Pharmaceuticals Holdings over the next 1-year time period is forecast to be $14.80 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is RVPH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Reviva Pharmaceuticals Holdings is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RVPH?
You can purchase shares of Reviva Pharmaceuticals Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Reviva Pharmaceuticals Holdings shares.
-
What Is The Reviva Pharmaceuticals Holdings Share Price Today?
Reviva Pharmaceuticals Holdings was last trading at $1.78 per share. This represents the most recent stock quote for Reviva Pharmaceuticals Holdings. Yesterday, Reviva Pharmaceuticals Holdings closed at $1.78 per share.
-
How To Buy Reviva Pharmaceuticals Holdings Stock Online?
In order to purchase Reviva Pharmaceuticals Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
